NBE-Therapeutics, Chief Executive Officer
The Swiss-based company is developing best in class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform. The first-in-human study with lead candidate NBE-002 is expected to commence in 2020, focusing on triple-negative breast cancer and lung cancer, as well as other solid cancer indications and lymphomas.
For its next phase, the company has welcomed Bertrand Damour as Chief Executive Officer. Damour has 20 years' management experience in the biotech industry in Europe and the US as CEO of biotech companies and in the banking industry. He was previously CEO of US proteomics company GeneProt Inc.; Mind NRG, a Swiss biotech company in the field of CNS (acquired by Minerva Neurosciences); OncoEthix, a Swiss-based oncology company in the field of epigenetics (acquired by Merck & Co. for US$375 million). More recently he was at Synthena AG, a company developing Oligonucleotide based therapeutics for the treatment of genetic neuromuscular diseases. Bertrand has extensive expertise in corporate transactions, including M&A, LBOs and IPOs gained while working in the banking industry at J.P. Morgan, Rabobank International and Deutsche Bank in New York and London.
Kandou, Chief Financial Officer
Kandou, an innovative leader in high-speed, energy-efficient, chip link solutions has announced a Jeff Winzeler as its new CFO. Previously, Winzeler was CFO of Everspin Technologies where he helped build the foundation for its growth and lead it through its 2016 IPO. Prior experience includes serving as CFO for Avnera, Rackwise, Solar Power Inc. and International DisplayWorks. At each, he helped secure working capital for business growth, scaling these businesses through their exits. His expertise includes managing multiple disciplines, such as finance, information technology, human resources, operations, procurement, and investor relations. Winzeler began his career with Intel Corporation. At Kondou, his responsibilities range from financial operations and planning to investment strategy.
Droople, finance lead
Droople built a water intelligence platform to manage water-driven assets and buildings efficiently. The company aims to digitalise its water filtration systems with a retrofit solution based on a smart flow, temperature and hardness sensor and an AI-enabled cloud platform for vendors and service providers.
The company has welcomed Christian Hugo to its management board. Hugo is a serial entrepreneur with two fintech companies under. He brings broad expertise gained from his companies and his previous role as Head of Finance at Verity. He is also the director of Startup Grind in Geneva, a deputy director of the Swiss FinTech Innovation Lab, University of Zurich and Assistant Professor of Finance and Fintech at the University of Liechtenstein. At Droople, Hugo will lead Finance, Investor relations, Governance and will be in charge of the preparation and closure of our Series A by Q3 2021. He will also coordinate our R&D activities on AI with our academic partners.
Cellestia Biotech, Chief Medical Office
Basel based Cellestia Biotech is a biopharmaceutical company specialised in research and development of first-in-class drugs targeting gene transcription factors enabling the treatment of multi-drug resistant cancers as well as a wide range of non-cancer indications a clinical-stage biopharma company developing innovative treatments for cancer. After closing a CHF 20 million Series B financing end of 2019, Cellestia is now preparing the launch of a global clinical program in EU, USA and Asia, to advance our lead molecule CB-103 into Phase 2 in a number of indications
Effective this month, Florian D. Vogl has assumed the position of Chief Medical Officer. Vogl is a board-certified MD with a PhD in clinical pharmacology from the University of Munich and completed a postdoctoral fellowship at the International Agency for Research on Cancer in Lyon. Before moving to the biopharmaceutical industry, he had a career as a physician and clinical researcher in gynaecology and oncology. Prior to joining Cellestia, Vogl was Head of Clinical Development Europe at a US-based biotech company. Previously he held roles of increasing responsibility at Novartis Oncology and Amgen in Europe and in the USA.
Photo L-R: Bertrand Damour, Jeff Winzeler, Christian Hugo and Florian D. Vogl